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A B S T R A C T
Purpose: To assess the impact of perceived stigma on the quality of life of Bulgarian patients with
refractory epilepsy.
Methods: We studied 70 adult patients with refractory epilepsy, without cognitive impairment,
progressive somatic, neurological disease or recent seizures, and 70 patients with pharmacosensitive
epilepsy. All participants completed a 3-item stigma scale, the patients with refractory epilepsy also
completed a Health Related Quality of Life measure (the QOLIE-89).
Results: The patients with refractory epilepsy had a mean disease duration 25.1  1.3 years. 40.0% of
patients (5.9) had symptomatic epilepsy. Seventeen patients (24.2%  5.1) had partial seizures, 16
(22.8%  5.0) had generalized seizures and 37 (52.9  6.0) had a mixture of partial and generalized seizures.
Most participants had several seizures per week (45.7%) or month (30.0%) despite the fact that 90% were
taking combination antiepileptic drug treatment. We found perceived stigma in 43.6% of patients with
refractory epilepsy, and 28.7% self-reported severe stigmatization. Only 4 (5.7%) patients with
pharmacosensitive epilepsy reported stigmatization which was mild or moderate in all cases. Perceived
stigma had a negative impact on the overall score of the QOLIE-89 (T-score 47.8), as well as on all subscales of
QOLIE-89, with the exception of ‘‘change in health’’ and ‘‘sexual relations’’. Patients with refractory epilepsy
reporting stigmatization most commonly had very low and low scores on the subscales ‘‘health perceptions’’
(82.9%), ‘‘emotional well-being’’ (71.5%), ‘‘memory’’ (63.4%) and ‘‘health discouragement’’ (62.5%). There was
a negative correlation of all QOLIE-89 subscales with perceived stigma severity.
Conclusion: All aspects of the quality of life of Bulgarian patients with refractory epilepsy correlate
negatively with the severity of perceived stigma.
 2012 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
Contents lists available at SciVerse ScienceDirect
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Stigma was deﬁned by Link and Phelan (2001) as a social
process that is observed when there are elements of labeling,
stereotyping, and discrimination because of characteristics previ-
ously speciﬁed as different and unacceptable, which result in social
status loss.1 Health-related stigma is based on a special character-
istic of a health problem or a state.2 Stigma worries the patient
more than the disease itself, makes the patient feel guilty, and is
associated with depression.3 In patients with epilepsy, stigma is a
result of the unpredictability of seizures and social exclusion due to
a negative attitude of society, including difﬁculties in education,
having a family, and ﬁnding a job, even when it is not
contraindicated.4 Because of stigmatization, patients hide the
disease from relatives, partners, and employers.5 The frequency of
stigmatization varies from 31% to 54%, and in 9% to 29.3% of
patients, it is severe.3 In persons with epilepsy, perceived stigma
(i.e., feelings of devaluation, shame, secret, or withdrawal caused* Correspondence address: 4002 Plovdiv, 15A Vasil Aprilov str., University of
Medicine, Department of Neurology, Bulgaria. Tel.: +359 887752235.
E-mail address: eiviteva@abv.bg.
1059-1311/$ – see front matter  2012 British Epilepsy Association. Published by Else
http://dx.doi.org/10.1016/j.seizure.2012.10.010by applying negative stereotypes to the subject) has been
investigated most frequently by means of appropriate question-
naires.
Epilepsy has a great inﬂuence on the three levels of quality of
life (physical, mental and social health), an inﬂuence that is
exercised directly by affecting physical and mental health and
indirectly by introducing limitations and decreasing the opportu-
nities for taking part in quality of life improving activities. The
results from a number of studies have proven that the stigmatiza-
tion in this group of patients is one of the factors contributing to
quality of life decrease.6–9
No study of stigma and its impact on the quality of life of
patients with epilepsy has been performed in Bulgaria.
1.1. Purpose of the study
Assessment of the impact of perceived stigma on the quality of
life of Bulgarian patients with refractory epilepsy.
1.2. Patients and methods
The study was performed with the participation of 176
consecutive patients with refractory epilepsy and 70 consecutivevier Ltd. All rights reserved.
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of Neurology at the University Hospital in Plovdiv, Bulgaria for a
regular examination, for cases of unsatisfactory seizure control or
for adverse events from treatment.
All study procedures were performed after the approval of the
Local Ethics Commission at the University of Medicine, Plovdiv.
Every patient was introduced to the study design and signed an
informed consent form before participation in study procedures.
We used the following inclusion criteria: a signed informed
consent form; age between 18 and 65 years; a diagnosis of
refractory epilepsy; lack of cognitive impairment based on
Evaluation Rapide des Fonctions Cognitives (ERFC; Gil and Toullat,
1986), with a score <47 in patients up to 60 years of age and
primary education or <46 in patients between 60 and 65 years of
age and less than a primary education or illiterate; lack of
progressive somatic or neurological disease; lack of simple or
complex partial seizures in the last 4 h; and lack of generalized
tonic-clonic seizures in the last 24 h. We accepted epilepsy as
refractory in cases in which adequate seizure control with at least
two potentially effective antiepileptic drugs prescribed as mono-
therapy or combination at maximal tolerated doses had not been
achieved. After excluding 39 patients with pseudo-refractory
epilepsy (in cases with diagnostic, therapeutic errors or poor
compliance), 2 patients older than 65 years, 2 patients with
progressive neurological disease, 5 patients with a simple or
complex partial seizures in the last 4 h or a generalized tonic-clonic
seizure in the last 24 h, and 58 patients with cognitive impairment,
70 patients with refractory epilepsy and 70 patients with
pharmacosensitive epilepsy remained in the study.
The data were collected through an interview and examination
of the patients’ medical documentation.
Twenty one (30.0%  5.5) of the participants with refractory
epilepsy were men; the remaining 49 (70.0%  5.5) were women. The
mean patient age was 41.7  1.1 years. Most participants (76.6%)
were between 30 and 60 years of age. The mean disease duration was
25.1  1.3 years. Of the patients with pharmacosensitive epilepsy, 34
(48.6%) were men, and 36 (51.4%) were women; their mean age was
36.7  1.5 years. There was no signiﬁcant difference between both
groups regarding their gender (P > 0.05, x2 = 2.4) and age (P > 0.05,
u = 0.6).
Patients with refractory epilepsy and pharmacosensitive
epilepsy completed the stigma scale (MD Hyman, 1971); a Health
Related quality of life measure (the QOLIE-89) was completed only
by patients with refractory epilepsy. The stigma scale consists of
three questions pertaining to patients’ opinions about the attitudes
of people. The possible answers are ‘‘yes’’ and ‘‘no.’’ The severity of
perceived stigma depends on the number of positive answers. If
there is one afﬁrmative response, we accepted the patient as
stigmatized. The scale scores are as follows: 0 = ‘‘none’’, 1 = ‘‘mild’’,
2 = ‘‘moderate’’, and 3 = ‘‘severe’’. The scale has been applied by
Jacoby et al.1 in patients with epilepsy, and is known to have
satisfactory convergent validity and internal consistency.2
QOLIE-89 is the most understandable and most widely used
instrument for quality of life assessment in patients with epilepsy.
It is the scale that includes the greatest number of epilepsy-
associated factors. QOLIE-89 has been approved for research, and it
is completed in 45 min. This scale enables the discrimination of
minimally expressed but signiﬁcant life quality changes in these
patients. QOLIE-89 contains 89 items that are distributed in 17
subscales, characterizing 4 basic factors directed toward epilepsy,
physical, mental, and social health. Except for the standard scores,
the so-called ‘‘G-scores’’ for each of the 17 scale ﬁnal scores and the
overall score are calculated. The T-scores represent linear
transformations of the scores that produce a mean of 50 and a
standard deviation of 10 for the cohort of 304 adults with epilepsy.
Higher T-scores reﬂect a more favorable quality of life.In the course of the study, we made a validation of the Bulgarian
translation of QOLIE-89 and proved its reliability, internal
consistency (the mean of Crohnbach’s a was 0.9  0.0; the
coefﬁcient of Spearman–Brown was 0.9; the mean inter-item
correlation was 0.3; we calculated a high coefﬁcient of correlation
between the subscales scores and the overall score in two
completions of the questionnaire [rxy = 0.8–1.0]) and validity (strong
correlations between the overall scores of QOLIE-89 and QOLIE-31
[rxy = 0.9] and between their corresponding subscales were found
[rxy = 0.9–1.00]).
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The collected primary information was checked, encoded, and
entered into a computer database for statistical analysis. Data were
processed using STATA Version 10 (Stata Corp., College Station, TX,
U.S.A.) and SPSS (Statistical Package for the Social Sciences),
version 14.0 (SPSS Inc., Chicago, IL, USA). The results for
quantitative variables were expressed as the mean  SE (standard
error), and the results for qualitative variables were expressed as
percentages  SE. Age, gender, clinical ﬁndings, stigmatization of
patients with refractory and pharmacosensitive epilepsy, as well as
the assessments of the subscales and the overall score of QOLIE-89
made by stigmatized and non-stigmatized patients, were compared
by means of x2-test and Z-test. Spearman coefﬁcient (rs) was used to
analyze the correlation between stigma and the assessments of the
subscales, as well as the overall score of QOLIE-89. Pairwise
comparisons between the scores of the non-stigmatized patients
and those of the mildly to moderately stigmatized patients were
performed according to the Hochberg procedure to maintain an
overall 5% type I error.
2. Results
2.1. Clinical ﬁndings of study participants
The clinical ﬁndings of the study participants are shown in
Table 1.
2.2. Perceived stigma of study participants
According to the results from the stigma scale, 26 (37.1%) of the
patients with refractory epilepsy reported stigmatization. Seven
(10%) of all participants with refractory epilepsy were mildly
stigmatized, 3 (4.3%) were moderately stigmatized, and 16 (22.9%)
were severely stigmatized. Only 4 (5.7%) patients with pharma-
cosensitive epilepsy were mildly or moderately stigmatized. There
were no participants with both pharmacosensitive epilepsy and
severe stigmatization. With respect to the perceived stigma, a
signiﬁcant difference between patients with refractory and
pharmacosensitive epilepsy was demonstrated (P < 0.001,
x2 = 23.0).
2.3. QOLIE-89 results
The mean overall score of QOLIE-89 given by the patients with
refractory epilepsy was 64.3  17.1. In our data analysis, the T-
scores were used for a more explicit comparison with the mean scores
of the epileptic population. The obtained scores were accepted as very
low (35), low (36–45), medium (46–55) and high (>55). As a T-
score, the mean overall score of QOLIE-89 was lower than the mean of
the epileptic population (x = 47.8). Low mean scores were obtained
for the subscales ‘‘Health perceptions’’ (x = 39.4), ‘‘Sexual relations’’
(x = 42.5) and ‘‘Overall quality of life’’ (x = 42.8). The mean scores of all
other subscales were close to the mean of the epileptic population.
The subscales of QOLIE-89 were distributed in the following 5
groups: subscales associated with physical health, subscales
associated with mental health, subscales associated with social
health, subscales associated with epilepsy, and subscales associated
Table 1
Clinical ﬁndings of the study participants.
Refractory epilepsy Pharmacosensitive epi-
lepsy
x2/Z P
N P (%)  SE N P (%)  SE
Type of epilepsy
Partial 53 75.7  5.1 24 34.3  5.7 x2 = 26.4 <0.001
Generalized 17 24.3  5.1 46 65.7  5.7
Etiology of epilepsy
Idiopathic 17 24.3  5.1 30 42.9  5.9 x2 = 5.4 >0.05
Symptomatic 28 40.0  5.9 21 30.0  5.5
Cryptogenic 25 35.7  5.7 19 27.1  5.3
Type of seizures
Partial 17 24.3  5.1 24 34.3  5.7 x2 = 52.7 <0.001
Generalized 16 22.9  5.0 46 65.7  5.7
A mixture of partial and generalized seizures 37 52.8  6.0 – –
Recent seizure frequency
Without seizures in recent years – – 70 100.0 <0.001
1/several years 2 2.9  – – – Z = 11.0
1–11 seizures/year 11 15.7  4.35 – –
1–3 seizures/month 21 30.0  5.48 – –
1–6 seizures/week 32 45.7  5.95 – –
Daily seizures 4 5.7  – – –
Therapy
Monotherapy 7 10.0  3.6 61 87.1  4.0 x2 = 83.4 <0.001
Combination antiepileptic drug treatment 63 90.0  3.6 9 12.9  4.0
P (%): percentage of patients; SE: standard error.
E. Viteva / Seizure 22 (2013) 64–6966with a more general assessment, e.g., ‘‘overall health’’ and ‘‘overall
quality of life’’. For the purpose of data analysis, the overall QOLIE-89
score was also included in the last group.
2.4. QOLIE-89 results of the stigmatized and non-stigmatized patients
The distribution of the patients with refractory epilepsy with
and without perceived stigma according to the scores of the
subscales and the overall score of QOLIE-89 is presented in Fig. 1.
2.5. Impact of perceived stigma on physical health
The perceived stigma has an impact on most aspects of the
physical health, except for the subscales ‘‘change in health’’ (x2 = 0.9,
P > 0.05) and ‘‘sexual relations’’ (x2 = 1.0, P > 0.05). After perform-
ing the Hochberg step-up test, no signiﬁcant difference in the scores
for both subscales was found between the stigmatized, the mildly to
moderately stigmatized, and the severely stigmatized patients.
Very low and low scores for the subscale ‘‘health perceptions’’
were obtained from 58.5% of the stigmatized patients and 24.4% of
the patients with stigma, as opposed to 27.5% and 37.3% of the
participants without perceived stigma (x2 = 10.4, P < 0.01). High
scores for the same subscale were obtained only from 2.4% of the
stigmatized participants and 13.7% of the non-stigmatized
participants. The correlation was moderate, and the reverse
P < 0.01 (rs = 0.4). After performing the Hochberg step-up test,
no signiﬁcant difference in the scores for this subscale was found
among the stigmatized, the mildly to moderately stigmatized, and
the severely stigmatized patients.
As for the subscale ‘‘physical function’’, 20% of the stigmatized
participants gave very low scores and 25% gave low scores, as
opposed to 5.7% and 11.3%, respectively, of the non-stigmatized
patients (x2 = 8.8, P < 0.01). High scores were obtained from 32.5%
of the stigmatized patients and from 49.1% of those without
stigma. The correlation was moderate, and the reverse P < 0.01
(rs = 0.4). The correlation was signiﬁcant, and the reverse
P < 0.001 (rs = 0.5). After performing the Hochberg step-up test,
a signiﬁcant difference in the scores for this subscale was
demonstrated between the non-stigmatized and the mildly to
moderately stigmatized patients.According to the interviewed patients, the physical limitations
in cases with perceived stigma were signiﬁcant: 31.7% gave very
low scores for this subscale, and 26.8% gave low scores, as opposed
to 5.7% and 13.2%, respectively, of the non-stigmatized patients
(x2 = 17.2, P < 0.01). High scores were obtained from 31.7% of the
stigmatized participants and from 62.3% of the non-stigmatized
cases. The correlation was moderate, and the reverse P < 0.001
(rs = 0.5). The correlation was signiﬁcant, and the reverse
P < 0.001 (rs = 0.5). After performing the Hochberg step-up test,
a signiﬁcant difference in the scores for this subscale was observed
between the non-stigmatized and the severely stigmatized
patients.
Perceived stigma correlated with a more frequent and a
stronger feeling of pain (x2 = 10.6, P < 0.05). Very low and low
scores for this subscale were obtained from 33.3% and 20.5% of the
stigmatized patients, and high scores were obtained from 28.2%.
The non-stigmatized patients gave very low or low scores much
more rarely – 6.4% and 23.5%, respectively; the high assessments
were much more frequent (46.8%). The correlation was moderate,
and the reverse P < 0.01 (rs = 0.4). After performing the Hochberg
step-up test, no signiﬁcant difference in the scores for this subscale
was found among the stigmatized, the mildly to moderately
stigmatized, and the severely stigmatized patients.
Perceived stigma had also an impact on the assessments of the
subscale ‘‘energy/fatigue’’ (x2 = 10.3, P < 0.01). The fatigue was
perceived as signiﬁcant by the stigmatized patients, as 24.2% of
them gave very low scores, and 33.3% gave low scores for this
subscale, as opposed to 2.0% and 38.8%, respectively, of the non-
stigmatized patients. High scores were obtained from 18.2% of the
stigmatized participants and from 30.6% of the non-stigmatized
cases. The correlation was moderate, and the reverse P < 0.01
(rs = 0.4). After performing the Hochberg step-up test, no
signiﬁcant difference in the scores for this subscale was found
among the stigmatized, the mildly to moderately stigmatized, and
the severely stigmatized patients.
The greatest inﬂuence of the perceived stigma on the subscale
‘‘health discouragement’’ was observed (x2 = 26.1, P < 0.01).
Obviously, the negative attitude toward the patient and the
disease determines a more pessimistic feeling for health status:
62.5% of the stigmatized participants gave very low scores, and
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Fig. 1. Distribution of the patients with refractory epilepsy with and without stigma according to the scores of the subscales and the overall score of QOLIE-89.
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from 2.5% of the stigmatized participants and from 35.8% of the
non-stigmatized cases. The correlation was signiﬁcant, and the
reverse P < 0.001 (rs = 0.5). After performing the Hochberg step-
up test, a signiﬁcant difference in the scores for this subscale was
observed among the non-stigmatized, the mildly to moderately
stigmatized, and the severely stigmatized patients.
As a whole, the perceived stigma has a deﬁnite negative impact
on most aspects of physical health, which is most likely associated
with the suggestion of low self-esteem regarding the physical
problems.
2.6. Impact of perceived stigma on mental health
Perceived stigma has an impact on all aspects of mental
health.
It results in increased emotional limitations (x2 = 13.6,
P < 0.01). Only 15.4% of the non-stigmatized patients gave very
low scores for the subscale ‘‘emotional limitations’’, as opposed to
42.5% of the stigmatized patients; 75.5% of the non-stigmatized
participants and 48.5% of the stigmatized patients gave high scores.
The correlation was signiﬁcant, and the reverse P < 0.01 (rs = 0.5).After performing the Hochberg step-up test, a signiﬁcant differ-
ence in the scores for this subscale was observed between the non-
stigmatized and the severely stigmatized patients.
Perceived stigma also has a negative impact on the subscale
‘‘emotional well-being’’ (x2 = 17.5, P < 0.01). There was a signiﬁcant
difference between the percentage of the non-stigmatized partici-
pants, with low scores for this subscale (29.2%), and the percentage
of the stigmatized patients (71.5%): 27.1% of the non-stigmatized
patients and 15.8% of the stigmatized patients gave high scores for
this subscale. The correlation was moderate, and the reverse
P < 0.01 (rs = 0.4). After performing the Hochberg step-up test, a
signiﬁcant difference in the scores for this subscale was observed
between the non-stigmatized and the severely stigmatized patients.
Perceived stigma also has a negative impact on the assessment
of the following cognitive functions: attention/concentration
(x2 = 10.1, P < 0.01), memory (x2 = 24.6, P < 0.01), and language
(x2 = 9.4, P < 0.05): 42.9% of the non-stigmatized patients gave
high scores for the subscale ‘‘attention/concentration’’, as opposed
to 13.9% of the stigmatized patients; 58.3% of the stigmatized
participants and 31% of the non-stigmatized patients determined
that these cognitive functions had been disturbed. The correlation
was signiﬁcant, and the reverse P < 0.01 (rs = 0.5). After
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the scores for this subscale was found among the stigmatized, the
mildly to moderately stigmatized, and the severely stigmatized
patients.
The percentage of stigmatized patients who gave very low and
low scores for the subscale ‘‘memory’’ was 63.4%, as opposed to
12.8% of the non-stigmatized patients; 22% of the stigmatized
participants and 46.8% of the non-stigmatized patients gave high
scores for this subscale. The correlation was signiﬁcant, and the
reverse P < 0.01 (rs = 0.5). After performing the Hochberg step-up
test, no signiﬁcant difference in the scores for this subscale was
found among the stigmatized, the mildly to moderately stigma-
tized, and the severely stigmatized patients.
For the ‘‘language’’ subscale, 77.4% of the non-stigmatized
patients and 47.5% of the stigmatized patients claimed that they
did not have language problems: 11.4% of the non-stigmatized
participants, compared with 22.5% of the stigmatized patients,
gave very low and low scores. The correlation was moderate, and
the reverse P < 0.05 (rs = 0.4). After performing the Hochberg
step-up test, no signiﬁcant difference in the scores for this subscale
was found among the stigmatized, the mildly to moderately
stigmatized, and the severely stigmatized patients.
2.7. Impact of perceived stigma on social health
Perceived stigma inﬂuences all aspects of social health.
The negative impact of perceived stigma on the assessment of
the subscale ‘‘work/driving/social function’’ was demonstrated
(x2 = 26.5, P < 0.01): i.e., it is associated with limited opportunities
for professional realization, driving and other social functions.
Additionally, more severe stigma results in more limited social
functions. The percentage of non-stigmatized patients who gave
high scores for this subscale was 46.2%: in cases with mild to
moderate stigma, it decreased to 7.1%, whereas none of the
participants with severe stigma perceived these functions as
preserved. Only 3.8% of the non-stigmatized participants, 7.1% of
those with mild to moderate stigma, and 24% of the patients with
severe stigma gave very low scores for this subscale. The
correlation was signiﬁcant, and the reverse P < 0.001 (rs = 0.5).
After performing the Hochberg step-up test, no signiﬁcant
difference in the scores for this subscale was observed among
the stigmatized, the mildly to moderately stigmatized, and the
severely stigmatized patients.
Perceived stigma has a negative impact on the assessment of
the subscale ‘‘social support’’ as well (x2 = 17.2, P < 0.01): i.e., it
correlates directly with poorer social support. Additionally, more
severe stigma results in poorer social support. The percentage of
non-stigmatized patients who gave high scores for this subscale
was 70%, but in cases with mild to moderate stigma, it decreased to
54.5%; 32% of the participants with severe stigma perceived the
social support as sufﬁcient. Only 4% of the non-stigmatized
participants and 28% of the patients with severe stigma gave very
low scores for this subscale. The correlation was signiﬁcant, and
the reverse P < 0.001 (rs = 0.5). After performing the Hochberg
step-up test, no signiﬁcant difference in the scores for this subscale
was found among the stigmatized, the mildly to moderately
stigmatized, and the severely stigmatized patients.
Perceived stigma has a negative impact on the assessment of
the subscale ‘‘social isolation’’ (x2 = 25.1, P < 0.001): i.e., it
correlates with more pronounced social isolation. More severe
stigma results in more pronounced social isolation. The percentage
of non-stigmatized patients who gave high scores for this subscale
was 65.4%, but in cases with mild to moderate stigma, it decreased
to 53.8%. Only 38.4% of the participants with severe stigma
perceived the social isolation as lacking or poorly pronounced.
Only 3.8% of the non-stigmatized participants and 43.5% of thepatients with severe stigma gave very low scores for this subscale.
The correlation was moderate, and the reverse P < 0.001
(rs = 0.4). The correlation was signiﬁcant, and the reverse
P < 0.001 (rs = 0.5). After performing the Hochberg step-up test,
a signiﬁcant difference in the scores for this subscale was found
among the non-stigmatized, the mildly to moderately stigmatized,
and the severely stigmatized patients.
2.8. Impact of the perceived stigma on the quality of life aspects
associated with epilepsy
Perceived stigma has a negative impact on both aspects
associated with epilepsy.
The stigmatized patients gave very low and low scores for the
subscale ‘‘medication effects’’ much more frequently (39.4%)
compared to the non-stigmatized patients (24.5%) [x2 = 12.1,
P < 0.05]: 26.3% of the stigmatized participants gave high scores
compared to twice as many of the non-stigmatized patients
(55.1%). After performing the Hochberg step-up test, no signiﬁcant
difference in the scores for this subscale was found among the
stigmatized, the mildly to moderately stigmatized, and the
severely stigmatized patients.
To assess the ‘‘seizure worry’’ subscale, 39.2% of the non-
stigmatized patients and 52.9% of the stigmatized ones gave very
low and low scores (x2 = 13.3, P < 0.05). The percentage of non-
stigmatized participants who gave high scores was much greater
(39.2%) compared with the stigmatized patients (14.3%). The
correlation was moderate, and the reverse P < 0.01 (rs = 0.3).
These results prove that the perceived stigma correlates with more
pronounced worries about seizures and side effects of antiepileptic
drugs. The increase in stigma severity results in lower scores for
the subscale ‘‘seizure worry’’. After performing the Hochberg step-
up test, no signiﬁcant difference in the scores for this subscale was
found among the stigmatized, the mildly to moderately stigma-
tized, and the severely stigmatized patients.
2.9. Impact of perceived stigma on the subscales ‘‘overall health’’,
‘‘overall quality of life’’ and the overall score of QOLIE-89
Perceived stigma has a negative impact on the subscales
‘‘overall health’’ and ‘‘overall quality of life’’, as well as on the
overall score of QOLIE-89.
Only 22.6% of the non-stigmatized patients gave very low and
low scores for the subscale ‘‘overall health’’, compared with
28.5% of the participants with mild to moderate stigma and
62.9% of those with severe stigma (x2 = 22.8, P < 0.01); 18.5% of
the severely stigmatized patients gave high scores in contrast to
the patients with mild to moderate stigma (28.6%) and the non-
stigmatized patients (45.3%). The correlation was moderate, and
the reverse P < 0.01 (rs = 0.4), i.e., more severe stigma results
in lower scores for the subscale ‘‘overall health.’’ After
performing the Hochberg step-up test, no signiﬁcant difference
in the scores for this subscale was observed among the
stigmatized, the mildly to moderately stigmatized, and the
severely stigmatized patients.
As for the subscale ‘‘overall quality of life’’, 54.7% of the non-
stigmatized patients gave very low and low scores compared with
66.7% of the participants with mild to moderate stigma and 90.9%
of those with severe stigma (x2 = 21.9, P < 0.01). None of the
stigmatized patients gave similar scores, which contrasted with
the non-stigmatized patients (17%). The correlation was signiﬁ-
cant, and the reverse P < 0.01 (rs = 0.5), i.e., more severe stigma
results in lower scores for the subscale ‘‘overall quality of life’’.
After performing the Hochberg step-up test, a signiﬁcant differ-
ence in the scores for this subscale was observed between the non-
stigmatized and the severely stigmatized patients.
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and low scores were calculated for 26% of the non-stigmatized
patients, as well as 53.9% of the participants with mild stigma and
73.1% of the participants with severe stigma (x2 = 21.9, P < 0.01).
High scores were calculated for 3.8% of the patients with severe
stigma, but none were calculated for those with mild to moderate
stigma and 46% of the non-stigmatized participants had high
scores. The correlation was signiﬁcant, and the reverse P < 0.01
(rs = 0.6). In conclusion, perceived stigma has an important
negative impact: more severe stigma results in a lower overall
QOLIE-89 score. The correlation was signiﬁcant, and the reverse
P < 0.001 (rs = 0.5). After performing the Hochberg step-up test, a
signiﬁcant difference in the scores for this subscale was found
among the non-stigmatized, the mildly to moderately stigmatized,
and the severely stigmatized patients.
3. Discussion
The purpose of this study was to assess the impact of perceived
stigma on the quality of life of adult patients with refractory
epilepsy. The obtained results have proven that perceived stigma
correlates with lower scores for most subscales of QOLIE-89
(except for ‘‘change in health’’ and ‘‘sexual relations’’), as well as
the overall score of QOLIE-89. The greatest percentage of
stigmatized patients with very low and low scores was for the
subscales ‘‘health perceptions’’ (82.9%), ‘‘emotional well-being’’
(71.5%), ‘‘memory’’ (63.4%), ‘‘health discouragement’’ (62.5%), ‘‘role
limitations – physical’’ (58.5%), ‘‘attention/concentration’’ (58.3%),
and ‘‘energy/fatigue’’ (57.5%). Regarding the assessment of the
subscale ‘‘overall quality of life’’, 90.9% of the patients with severe
stigma and 66.7% of those with mild and moderate stigma gave
very low and low scores. Very low and low scores for the overall
assessment of QOLIE-89 have been calculated for 73.1% of the
patients with severe stigma and 53.9% of those with mild and
moderate stigma. We have concluded that perceived stigma has a
negative impact on all aspects of quality of life. There is a reverse
correlation (from mild to signiﬁcant): more severe stigma results
in lower scores for the corresponding subscale. In the utmost
degree, this correlation is valid for the subscale ‘‘health discour-
agement’’ P < 0.001 (rxy = 0.5) and the overall score of QOLIE-89
P < 0.01 (rxy = 0.6). Proofs about the negative impact of stigma on
the quality of life have been found in the scientiﬁc literature as
well.6,7 Whatley et al. have proven a similar negative correlation
between stigma and quality of life P < 0.001 (rxy = 0.5) and have
determined that stigma is a signiﬁcant predictor of a decreased
quality of life.9 According to Salgado et al., stigma changes the
patient’s self-esteem and limits the available work opportunities;
as a result, quality of life is signiﬁcantly decreased.8
4. Limitations
The ﬁrst limitation of our study is that we investigated
perceived stigma of patients with refractory and pharmacosensi-
tive epilepsy. Further investigations, not only on perceived stigmabut also on enacted stigma, as well as an objective assessment of
the attitude of Bulgarian society toward patients with epilepsy, are
needed. Another limitation is that patients with refractory epilepsy
completed QOLIE-89 because of the proven signiﬁcant difference
in stigma between the patients with RE and those with
pharmacosensitive epilepsy. To adequately complete both the
Stigma scale and QOLIE-89, we excluded patients older than 65
years, as well as those having cognitive impairment, progressive
neurological disease, and those with either simple or complex
partial seizures in the last 4 h or generalized tonic-clonic seizures
in the last 24 h. The participation of only those patients that had
access to the University Clinic of Neurology, as they usually
attended it for either a regular examination or in cases of
unsatisfactory seizure control or adverse events from treatment,
is also a limitation. These limitations do not devalue the results
from the ﬁrst Bulgarian study of perceived stigma in patients with
epilepsy and its impact on their quality of life. Further investiga-
tions of patients having different demographic, clinical and social
characteristics are needed.
5. Conclusion
In conclusion the demonstration of the stigma role in decreased
quality of life in patients with epilepsy contributes to the attention
that this problem has drawn in Bulgaria, as well as all over the
world, and illustrates the necessity of a multidisciplinary approach
in dealing with these patients. Doing so will give us opportunities
for a broader campaign, with the aim of ‘‘getting epilepsy out of the
shadows’’ by increasing the role of epileptic patient associations,
media, improving the education of medical and non-medical staff,
and encouraging the government to give additional ﬁnancial aid to
patients and their families and invest in educational programs and
research.
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